Market closedNon-fractional
Savara/SVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
SVRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Langhorne, United States
Employees
37
Website
www.savarapharma.com
Savara Metrics
BasicAdvanced
$753M
Market cap
-
P/E ratio
-$0.37
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$753M
Beta
0.72
Financial strength
Current ratio
14.902
Quick ratio
14.729
Long term debt to equity
21.848
Total debt to equity
21.968
Management effectiveness
Return on assets (TTM)
-30.22%
Return on equity (TTM)
-58.59%
Valuation
Price to book
5.21
Price to tangible book (TTM)
5.71
Price to free cash flow (TTM)
-13.183
Growth
Earnings per share change (TTM)
41.07%
3-year earnings per share growth (CAGR)
-18.56%
What the Analysts think about Savara
Analyst Ratings
Majority rating from 7 analysts.
Savara Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
26.88%
Profit margin
0.00%
NaN%
Savara Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.10
-$0.09
-$0.11
-
Expected
-$0.08
-$0.07
-$0.10
-$0.10
-$0.11
Surprise
-9.68%
38.89%
-13.18%
13.60%
-
Savara News
AllArticlesVideos
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
Benzinga·1 month ago
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire·1 month ago
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $753M as of July 27, 2024.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of July 27, 2024.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Savara stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.